RU2600976C2 - Производные азаиндазола или диазаиндазола в качестве медикамента - Google Patents

Производные азаиндазола или диазаиндазола в качестве медикамента Download PDF

Info

Publication number
RU2600976C2
RU2600976C2 RU2013138624/04A RU2013138624A RU2600976C2 RU 2600976 C2 RU2600976 C2 RU 2600976C2 RU 2013138624/04 A RU2013138624/04 A RU 2013138624/04A RU 2013138624 A RU2013138624 A RU 2013138624A RU 2600976 C2 RU2600976 C2 RU 2600976C2
Authority
RU
Russia
Prior art keywords
compound
group
formula
pyrazolo
pyridin
Prior art date
Application number
RU2013138624/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013138624A (ru
Inventor
Эль Бахир КАЛУН
Карим БЕДЖЕГЕЛАЛЬ
Реми РАБО
Анна КРЮЗИНСКИ
Филипп ШМИТТ
Мишель ПЕРЕС
Николя РАЙЕ
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2013138624A publication Critical patent/RU2013138624A/ru
Application granted granted Critical
Publication of RU2600976C2 publication Critical patent/RU2600976C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2013138624/04A 2011-01-27 2012-01-27 Производные азаиндазола или диазаиндазола в качестве медикамента RU2600976C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1150651 2011-01-27
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (2)

Publication Number Publication Date
RU2013138624A RU2013138624A (ru) 2015-03-10
RU2600976C2 true RU2600976C2 (ru) 2016-10-27

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013138624/04A RU2600976C2 (ru) 2011-01-27 2012-01-27 Производные азаиндазола или диазаиндазола в качестве медикамента

Country Status (30)

Country Link
US (2) US20130172360A1 (OSRAM)
EP (1) EP2668184B1 (OSRAM)
JP (1) JP5931926B2 (OSRAM)
KR (2) KR20180122028A (OSRAM)
CN (1) CN103339129B (OSRAM)
AR (1) AR084935A1 (OSRAM)
AU (1) AU2012210467B2 (OSRAM)
BR (1) BR112013018852B1 (OSRAM)
CA (1) CA2823824C (OSRAM)
CY (1) CY1120088T1 (OSRAM)
DK (1) DK2668184T3 (OSRAM)
ES (1) ES2661695T3 (OSRAM)
FR (1) FR2970967B1 (OSRAM)
HR (1) HRP20180524T1 (OSRAM)
HU (1) HUE037153T2 (OSRAM)
IL (2) IL227496B (OSRAM)
LT (1) LT2668184T (OSRAM)
MA (1) MA34903B1 (OSRAM)
MX (1) MX356411B (OSRAM)
MY (1) MY180666A (OSRAM)
PL (1) PL2668184T3 (OSRAM)
PT (1) PT2668184T (OSRAM)
RS (1) RS57101B1 (OSRAM)
RU (1) RU2600976C2 (OSRAM)
SI (1) SI2668184T1 (OSRAM)
TN (1) TN2013000293A1 (OSRAM)
TR (1) TR201802944T4 (OSRAM)
TW (1) TWI546303B (OSRAM)
UA (1) UA109698C2 (OSRAM)
WO (1) WO2012101239A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640046C2 (ru) * 2012-07-27 2017-12-26 Пьер Фабр Медикамент Производные типа азаиндазола или диазаиндазола для лечения боли
RU2792163C2 (ru) * 2018-05-02 2023-03-17 ДжейВ ФАРМАСЬЮТИКАЛ КОРПОРЕЙШН Новое гетероциклическое производное

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
WO2013126608A1 (en) 2012-02-22 2013-08-29 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112313232B (zh) * 2018-05-02 2024-03-08 Jw中外制药公司 新型杂环衍生物
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Fgfr阻害剤の塩
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
TW202136255A (zh) * 2019-12-31 2021-10-01 美商Ifm Due有限公司 用於治療與sting活性相關之病狀的化合物及組合物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115916771B (zh) * 2020-04-02 2025-04-01 浙江华海药业股份有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
WO2022106902A2 (en) 2020-11-20 2022-05-27 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT970084E (pt) * 1997-03-19 2003-10-31 Abbott Gmbh & Co Kg Pirrolo¬2,3d|pirimidinas e sua utilizacao como inibidores da tirosina-cinase
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
DK1292586T3 (da) 2000-06-22 2004-08-30 Pfizer Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
MX2008002385A (es) * 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos.
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
EA017852B1 (ru) 2006-12-20 2013-03-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные замещенных индазолов, активные в качестве ингибиторов киназ
NZ583450A (en) 2007-07-20 2012-05-25 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
WO2010069966A1 (en) 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOCEVAR M. ET AL "Neighbouring Group Participation in Formation of Condensed Azines. Formation of Pyrazolo(3,4-b)pyrazines, Isoxazolo(4,5-b)pyrazines and Isothiazolo(5,4-b)pyridine", Monatshefte fur Chemie, vol. 113, N 5, 1982,pages 731-744, exsample 10. KORBONITS D. ET AL "Ring Transformation of 3-(2-Aminoaryl)-1,2,4-oxadiazoles into 3-Acyl-aminoindazoles; 1 Extension of the Boulton-Katritzky Scheme", Journal of The Chemical Society, Perkin Trasactions I, vol.1, N 3, pages 759-766, Scheme 3, example 6.1. *
WO 98/41525 A1? 24.09.1998. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640046C2 (ru) * 2012-07-27 2017-12-26 Пьер Фабр Медикамент Производные типа азаиндазола или диазаиндазола для лечения боли
RU2792163C2 (ru) * 2018-05-02 2023-03-17 ДжейВ ФАРМАСЬЮТИКАЛ КОРПОРЕЙШН Новое гетероциклическое производное

Also Published As

Publication number Publication date
IL227496B (en) 2019-02-28
CA2823824C (en) 2018-12-11
MY180666A (en) 2020-12-04
IL257748A (en) 2018-04-30
TW201247664A (en) 2012-12-01
RU2013138624A (ru) 2015-03-10
HUE037153T2 (hu) 2018-08-28
HK1186737A1 (en) 2014-03-21
FR2970967B1 (fr) 2013-02-15
ES2661695T3 (es) 2018-04-03
PL2668184T3 (pl) 2018-06-29
RS57101B1 (sr) 2018-06-29
UA109698C2 (xx) 2015-09-25
JP5931926B2 (ja) 2016-06-08
CY1120088T1 (el) 2018-12-12
EP2668184B1 (en) 2018-01-10
LT2668184T (lt) 2018-04-10
US20130172360A1 (en) 2013-07-04
IL227496A0 (en) 2013-09-30
TN2013000293A1 (en) 2015-01-20
DK2668184T3 (en) 2018-03-12
IL257748B (en) 2020-06-30
PT2668184T (pt) 2018-03-13
NZ614432A (en) 2015-03-27
US20130085144A1 (en) 2013-04-04
KR101923751B1 (ko) 2018-11-29
CN103339129A (zh) 2013-10-02
AU2012210467A1 (en) 2013-09-12
KR20140014147A (ko) 2014-02-05
KR20180122028A (ko) 2018-11-09
WO2012101239A1 (en) 2012-08-02
EP2668184A1 (en) 2013-12-04
BR112013018852A2 (pt) 2017-08-15
JP2014503574A (ja) 2014-02-13
AU2012210467B2 (en) 2016-07-07
MX2013008673A (es) 2013-12-02
MA34903B1 (fr) 2014-02-01
SI2668184T1 (en) 2018-06-29
CN103339129B (zh) 2015-07-29
FR2970967A1 (fr) 2012-08-03
CA2823824A1 (en) 2012-08-02
BR112013018852B1 (pt) 2021-12-21
HRP20180524T1 (hr) 2018-05-04
US8883821B2 (en) 2014-11-11
MX356411B (es) 2018-05-24
TR201802944T4 (tr) 2018-03-21
TWI546303B (zh) 2016-08-21
AR084935A1 (es) 2013-07-10

Similar Documents

Publication Publication Date Title
RU2600976C2 (ru) Производные азаиндазола или диазаиндазола в качестве медикамента
CN104684554B (zh) 用于治疗疼痛的氮杂吲唑或二氮杂吲唑型衍生物
US9428510B2 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
HK1186737B (en) Derivatives of azaindazole or diazaindazole type as medicament
HK1207302B (en) Derivatives of azaindazole or diazaindazole type for treating pain
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.
NZ614432B2 (en) Derivatives of azaindazole or diazaindazole type as medicament